Evidence map›Paper›PMID 17210244›Full record

ArticleJournal of autoimmunity2006

Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies.

Yasmin Akbarali, Jennifer Matousek-Ronck, Laura Hunt, Leslie Staudt, Morris Reichlin, Joel M Guthridge, Judith A James

Open access · greenAbstract read
In one paragraph

Article in Journal of autoimmunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Primary biliary cirrhosis: what do autoantibodies tell us?World journal of gastroenterology · 2010
    Review
  6. Article
  7. Whither autoimmunity: the lessons of anti-CCP and B cell depletion.Clinical reviews in allergy & immunology · 2008
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yasmin AkbaraliArthritis and Immunology Program, Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, 825 NE 13th Street, Oklahoma City, OK 73104, USA.
Jennifer Matousek-Ronck
Laura Hunt
Leslie Staudt
Morris Reichlin
Joel M Guthridge
Judith A James
University of Oklahoma Health Sciences Center · USOklahoma Medical Research Foundation · US

Funding

THE EFFECTS OF ERK PATHWAY INHIBITION ON DNA METHYLATION IN SLEP20RR015577 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CENTOLA, MICHAEL B · 2000 to 2009
$21.5M
VALIDATING NOVEL GENES IMPLICATED IN LEUKOCYTE CHEMOTAXISP20RR020143 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2004 to 2011
$21.0M
Program Project in the Genetics of SLEP01AR049084 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2002 to 2012
$12.7M
THROMBOCYTOPENIA AND THE GENETICS OF SEVERE LUPUSP50AR048940 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI REICHLIN, MORRIS · 2002 to 2006
$5.8M
Fine specificity of scleroderma autoantibodiesR01AR048045 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2001 to 2005
$1.6M
GENETIC ANALYSIS OF EPITOPE SPREADINGR01AR045451 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 1999 to 2004
$602k
GENETIC ANALYSIS OF EPITOPE SPREADINGR29AR045451 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 1998 to 1998
–
NCRR NIH HHS P20 RR015577NCRR NIH HHS P20 RR020143NCRR NIH HHS RR020143NCRR NIH HHS RR15577NIAMS NIH HHS AR45451NIAMS NIH HHS AR48045NIAMS NIH HHS AR48940NIAMS NIH HHS AR49084NIAMS NIH HHS P01 AR049084NIAMS NIH HHS P50 AR048940NIAMS NIH HHS R01 AR045451NIAMS NIH HHS R01 AR048045
6 · The paper itself

Abstract

Autoantibodies to centromeric proteins are commonly found in sera of limited scleroderma and other rheumatic disease patients. To better understand the inciting events and possible pathogenic mechanisms of these autoimmune responses, this study identified the common antigenic targets of CENP-A in scleroderma patient sera. Utilizing samples from 263 anti-centromere immunofluorescence positive patients, 93.5% were found to have anti-CENP-A reactivity and 95.4% had anti-CENP-B reactivity by ELISA. Very few patient samples exclusively targeted CENP-A (2.7%) or CENP-B (4.2%). Select patient sera were tested for reactivity with solid phase overlapping decapeptides of CENP-A. Four distinct epitopes of CENP-A were identified. Epitopes 2 and 3 were confirmed by additional testing of 263 patient sera by ELISA for reactivity with these sequences constructed as multiple antigenic peptides. Inhibition CENP-A Western blots also confirmed the specificity of these humoral peptide immune responses in a subset of patient sera. The first three arginine residues (aa 4-6) of CENP-A appear essential for antibody recognition, as replacing these arginines with glycine residues reduced antibody binding to the expressed CENP-A protein by an average of 93.2% (range 80-100%). In selected patients with serial samples spanning nearly a decade, humoral epitope binding patterns were quite stable and showed no epitope spreading over time. This epitope mapping study identifies key antigenic targets of the anti-centromere response and establishes that the majority of the responses depend on key amino-terminal residues.

Indexed as

AdultAgedAged, 80 and overAmino Acid SequenceAutoantibodiesAutoantigensCentromere Protein ACentromere Protein BChromosomal Proteins, Non-HistoneEnzyme-Linked Immunosorbent AssayEpitope MappingFemaleHeLa CellsHumansMaleMiddle AgedAutoantibodiesAutoantigensCENPA protein, humanCENPB protein, humanCentromere Protein ACentromere Protein BChromosomal Proteins, Non-Histone

Identifiers

PMID17210244
PMCPMC1906738
OpenAlexW2085898566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.